The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10740 malaria professionals are enjoying the free benefits of MalariaWorld today

artemisinins

A Second Mechanism Employed by Artemisinins to Suppress Plasmodium Falciparum Hinges on Inhibition of Hematin Crystallization

November 28, 2020 - 15:58 -- Open Access
Author(s): 
Ma W, Balta VA, West R, Newlin KN, Miljanić OŠ, Sullivan DJ, Vekilov PG, Rimer JD
Reference: 
J Biol Chem. 2020 Nov 25:jbc.RA120.016115

Malaria is a pervasive disease that affects millions of lives each year in equatorial regions of the world. During the erythrocytic phase of the parasite life cycle, Plasmodium falciparum invade red blood cells, where they catabolize hemoglobin and sequester the released toxic heme as innocuous hemozoin crystals. Artemisinin-class drugs are activated in vivo by newly-released heme, which creates a carbon-centered radical that markedly reduces parasite density.

Anti-SARS-CoV-2 Potential of Artemisinins In Vitro

September 15, 2020 - 10:05 -- Open Access
Author(s): 
Cao R, Hu H, Li Y, Wang X, Xu M, Liu J, Zhang H, Yan Y, Zhao L, Li W, Zhang T, Xiao D, Guo X, Li Y, Yang J, Hu Z, Wang M, Zhong W
Reference: 
ACS Infect Dis. 2020 Sep 11;6(9):2524-2531

The discovery of novel drug candidates with anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) potential is critical for the control of the global COVID-19 pandemic. Artemisinin, an old antimalarial drug derived from Chinese herbs, has saved millions of lives. Artemisinins are a cluster of artemisinin-related drugs developed for the treatment of malaria and have been reported to have multiple pharmacological activities, including anticancer, antiviral, and immune modulation.

Clinical illness and outcomes in Nigerian children with late-appearing anaemia after artemisinin-based combination treatments of uncomplicated falciparum malaria

June 8, 2016 - 15:59 -- Open Access
Author(s): 
Sowunmi A, Akano K, Ayede A, Ntadom G, Aderoyeje T, Adewoye E, Fatunmbi B
Reference: 
BMC Infectious Diseases 2016, 16:240 (1 June 2016)

This was an open label study with the main objectives of evaluating the clinical features, the risk factors for, the temporal changes in haematocrit and the outcomes of a LAA in malarious children treated with artesunate-amodiaquine (AA), artemether-lumefantrine (AL) or dihydroartemisinin-piperaquine (DHP). 

Subscribe to RSS - artemisinins